Patents
Patents for C07K 14 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof (291,526)
11/2008
11/26/2008CN100436482C Long effective amalgamation protein of erythropoietin of human, preparing and purifying methods
11/26/2008CN100436480C Platelet glycoprotein IB-alpha variant fusion polypeptides and methods of use thereof
11/26/2008CN100436479C Human protooncogene and protein encoded therein
11/26/2008CN100436478C Novel pesticidal toxins
11/26/2008CN100436471C Polynucleotide for identifying polypeptide OT3 and coding OT3 of tumor cell and uses thereof
11/26/2008CN100436470C Polynucleotide for identifying polypeptide OT10 and coding OT10 of tumor cell and uses thereof
11/26/2008CN100435859C Methods and compositions for healing and repair of articular cartilage
11/26/2008CN100435846C Synthetic peptide vaccines for foot-and-mouth disease
11/26/2008CN100435845C Live attenuated vaccine against porcine pleuropneumonia
11/25/2008US7456337 Signal transduction stress-related proteins and methods of use in plants
11/25/2008US7456335 Nucleic acid sequences and their use in methods for achieving pathogen resistance in plants
11/25/2008US7456333 Transgenic non-human mammals that reproduce human pathologies of stem cell origins, such as chromosomal anomalies associated with chronic myeloid leukemia, B-cell acute lymphoblastic leukemia, T-cell acute or lymphoblastic leukemia, or with the migration of hematopoietic or embryonic stem calls.
11/25/2008US7456276 Peptide purification by means of metal ion affinity chromatography
11/25/2008US7456272 Neurotoxins with enhanced target specificity
11/25/2008US7456269 Alzheimer's disease secretase, APP substrates thereof, and uses thereof
11/25/2008US7456268 Purified morpholino modified oligonucleotide; anticarcinogenic and antitumor agents; medical diagnosis; wild-type p53-induced phosphatase1 (Wip1); gene expression inhibition; drug screening
11/25/2008US7456267 Anticarcinogenic agents; nervous system disorders, urogenital disorders; improved biocompatibility
11/25/2008US7456263 P53 binding T cell receptor molecules
11/25/2008US7456262 Methods and composition for modulating and detecting wisp activity
11/25/2008US7456261 PRO9830 antibodies
11/25/2008US7456257 Fusion proteins of interferon alpha muteins with improved properties
11/25/2008US7456256 Fibronectins; drug screening; treating cardiovascular/nervous system disorders
11/25/2008US7456255 Nogo receptor homologs that decrease inhibition of axonal elongation
11/25/2008US7456254 polyglycolic acid or polylactic acid or glycolic acid-lactic acid copolymer as biocompatible polymer having dispersed therein about 3%-5% (w/w) exendin-4 and about 2% (w/w) sucrose; antidiabetic agent
11/25/2008US7456253 Growth hormone releasing peptides
11/25/2008US7456252 Synthetic peptides to treat an autoimmune demylinating disease e.g., multiple sclerosis; an amino acid sequence having two tyrosine residues and a lysine complex with the myelin basic protein to modulate an immune response
11/25/2008US7456250 amino acid sequences which are active at certain thrombin receptors, used as cell growth factors, to promote neovascularization, cell proliferation and wound healing
11/25/2008US7456153 Comprise at least a tryptophan-containing cell adhesion recognition sequence; cancer modulating agent
11/25/2008US7456152 Peptide inhibitors of thrombin as potent anticoagulants
11/25/2008US7456150 Pulmonary delivery of active fragments of parathyroid hormone
11/25/2008US7456148 Using apolipoprotein as therapeutic agent which prevents and treats thrombosis in cardiovascular and ischemia-reperfusion injuries
11/25/2008US7456146 Anticarcinogenic agents for use in the treatment of cancer
11/25/2008US7456018 Human hepatoma lines, methods for obtaining same and uses thereof
11/25/2008US7456008 Modified virus comprising one or more non-native polypeptides
11/25/2008US7456000 Conjugate formed by reacting a first compound with a second compound (particularly biomacromolecules) in which the conjugation involves an electrophilic moiety; deactivation by reacing unreacted electrophilic moieties with a nucleophilic reagent (hydrazine or an alkylenediamine); immunoassay reagents
11/25/2008US7455994 Methods for producing Marburg virus proteins
11/25/2008US7455991 Serpentine transmembrane antigens expressed in human cancers and uses thereof
11/25/2008US7455990 Isolating hexose oxidase for use as tool in enhancement of nutrient quality of animal feeeds
11/25/2008US7455989 AKAP84 and its use for visualization of biological structures
11/25/2008US7455987 Signal sequences for preparing leu-hirudin by secretion by E. coli into the culture medium
11/25/2008US7455984 Immunoreactive and immunotherapeutic molecules
11/25/2008US7455981 Method of detecting broad-spectrum delta-endotoxins
11/25/2008US7455977 Methods of determining the level of human TBP-II with anti-TBP-II antibody
11/25/2008US7455972 Determining presence, absence or quantity of murine Norovirus-1 (MNV-1) in a murine tissue, organ or feces sample by synthesizing complementary DNA from the sample RNA and detecting MNV-1 cDNA if present by a Polymerase chain reaction if MNV-1
11/25/2008US7455970 Identifying a subject predisposed to ischemic stroke by determining the presence of a cytosine to thymine mutation at position -7351 of the upstream region of tissue plasminogen activator locus, which reduces the release rate of tissue plasminogen activator from endothelial cells into the circulation
11/25/2008US7455969 Highly permissive cell lines for hepatitis C virus RNA replication
11/25/2008US7455964 Genes from the 20q13 amplicon and their uses
11/25/2008US7455963 Antibodies to cyclin E2 protein
11/25/2008US7455841 Constitutive transport enhancer (CTE); Rev Responsive element (RRE); coding sequence for HIV-1 Rev, and a coding sequence for a desired protein that comprises a coding sequence for an HIV structural protein that includes an RRE and at least one CTE; genetic vaccines, gene therapy
11/25/2008US7455835 Administering soluble cytotoxic t-lymphocyte associated antigen (ctla4) molecule that binds a cell surface B7 molecule
11/25/2008US7455155 Impact absorbent assembly in slope protection systems
11/25/2008CA2476656C Immobilized bioactive hydrogel matrices as surface coatings
11/25/2008CA2323687C Mutant recombinant allergens
11/25/2008CA2303416C Repressed trans-activator system for characterization of protein-protein interactions
11/25/2008CA2295306C Dna polymerase-related factors
11/25/2008CA2268029C Therapeutic and diagnostic applications of laminin and laminin-derived protein fragments
11/25/2008CA2154294C Collagen-based matrix
11/25/2008CA2140971C A stable freeze-dried hirudin composition
11/25/2008CA1341586C Seed specific transcriptional regulation
11/20/2008WO2008141281A1 A modified secretion system to increase expression of polypeptides in bacteria
11/20/2008WO2008141190A1 Heterologous production of capreomycin and generation of new capreomycin derivatives through metabolic engineering
11/20/2008WO2008140814A1 Methods for detecting cardiac damage
11/20/2008WO2008140812A2 Compositions and methods comprising klk3, psca, or folh1 antigen
11/20/2008WO2008140637A2 Secreted staphylococcus aureus proteins and peptides for use in inhibiting activation of the complement system
11/20/2008WO2008140602A2 USE OF ANTAGONISTS OF THE INTERACTION BETWEEN HIV GP120 AND α4β7 INTEGRIN
11/20/2008WO2008140582A2 Production of anti-microbial peptides
11/20/2008WO2008140573A2 Methods for reversibly binding a biotin compound to a support
11/20/2008WO2008139496A1 Recombinant human insulin and a method thereof
11/20/2008WO2008139259A2 Fluorescent proteins for monitoring intracellular superoxide production
11/20/2008WO2008139243A1 Vm23 and vm24, two scorpion peptides that block human t-lymphocyte potassium channels (sub-type kv1.3) with high selectivity and decrease the in vivo dth-responses in rats
11/20/2008WO2008139163A1 Prognostic assay for determining t cell response to hla antigens and use thereof in field of tissue transplantation
11/20/2008WO2008138994A1 Anti-tumor drug, medicament, composition, and use thereof
11/20/2008WO2008138649A2 Signaling peptides
11/20/2008WO2008138475A1 Use of crmp1 as a marker for chronic psychiatric illnesses and monoclonal antibodies against crmp1
11/20/2008WO2008138348A1 Preparation of complexed lactalbumin
11/20/2008WO2008138229A1 Recombinant protein expression system with enhanced yield and immunogenicity
11/20/2008WO2008138189A1 Use of cthrc1 in diagnosing cancer of liver
11/20/2008WO2008138141A1 Labelled adrenomedullin derivatives and their use for imaging and therapy.
11/20/2008WO2008138129A1 Thuricin 17 for promoting plant growth and disease resistance and transgenic plants
11/20/2008WO2008138123A1 Screening assay to identify correctors of protein trafficking defects
11/20/2008WO2008138120A1 Avian influenza h5n1 hemagglutilin pseudotyped lentiviral vector system for rapid identification of antivirals and neutralizing polypeptides
11/20/2008WO2008121563A3 Modified fgf-21 polypeptides and their uses
11/20/2008WO2008119882A3 Screening methods based on human adam12 polypeptide and binding agents thereof
11/20/2008WO2008112008A9 Sensor proteins and assay methods
11/20/2008WO2008109596A3 Canine transient receptor potential v2 (ctrpv2) and methods of screening for trpv2 channel modulators
11/20/2008WO2008109433A3 Anti-angiogenic peptides
11/20/2008WO2008106660A3 Isolated phospholipid-protein particles
11/20/2008WO2008106429A3 Methods and compositions for the treatment of heart failure and other disorders
11/20/2008WO2008106175A3 Gene and protein expression profiles associated with the therapeutic efficacy of egfr-tk inhibitors
11/20/2008WO2008106134A3 Engineered anti-il-23r antibodies
11/20/2008WO2008104805A3 Proteins
11/20/2008WO2008104575A3 Immune system mediator
11/20/2008WO2008097863A3 Methods for producing yeast-based vaccines
11/20/2008WO2008097854A3 Method and substances for treating hpv infection
11/20/2008WO2008097844A3 Methods and compositions relating to the regulation of apoptosis by muc1 and bh3- containing proapoptotic proteins
11/20/2008WO2008095110A3 Compositions and methods for detecting cancers in a subject
11/20/2008WO2008086086A3 Glucagon analogs exhibiting enhanced solubility in physiological ph buffers
11/20/2008WO2008085828A3 Peptide modulators of angiogenesis and use thereof
11/20/2008WO2008083271A3 Methods and compositions for enhanced protein expression and purification
11/20/2008WO2008076290A3 Optimized non-canonical zinc finger proteins